Jay Kakadiya

Dr. Jay Kakadiya

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2025 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
IKIman Kiani
Iman Kiani
SMSaeed Mohammadzadeh
Saeed Mohammadzadeh
SMSana Mozaffari
Sana Mozaffari
HMHanieh Mahmoudzadeh
Hanieh Mahmoudzadeh
DLDhairya A Lakhani
Dhairya A Lakhani
VYVivek Yedavalli
Vivek Yedavalli
BACKGROUND: Mechanical thrombectomy has transformed the management of large-vessel occlusion stroke; however, a considerable proportion of patients fail to achieve functional recovery despite successful recanalization. This “futile recanalization” underscores the need to better understand imaging biomarkers that may predict poor outcomes following endovascular therapy. PURPOSE: To systematically review and synthesize evidence on neuroimaging biomarkers associated with futile recanalization after mechanical thrombectomy in acute ischemic stroke. DATA SOURCES: PubMed, Scopus, Web of Science, and Embase databases were searched up to March 2025, supplemented by manual reference screening. STUDY SELECTION: Eligible studies enrolled adult patients with anterior-circulation stroke who underwent thrombectomy, reported pre-treatment neuroimaging findings, and evaluated functional outcomes despite successful reperfusion. Case reports, reviews, abstracts, and non-human studies were excluded. DATA ANALYSIS: Two reviewers independently screened, extracted data, and assessed study quality using PROBAST. Randomeffects meta-analysis was performed where appropriate. Heterogeneity, publication bias, and sensitivity analyses were undertaken. DATA SYNTHESIS: Fifty-one studies were included. Lower ASPECTS scores were strongly associated with futile recanalization (OR ≈0.81). Core infarct volume showed inconsistent associations, whereas perfusion and collateral markers, including elevated hypoperfusion intensity ratio, delayed venous outflow, and poor collateral scores, demonstrated strong predictive value. Chronic white-matter injury, leukoaraiosis, and cerebral atrophy were also consistently associated with worse outcomes. LIMITATIONS: Heterogeneity in imaging protocols and thresholds; predominance of retrospective single-center cohorts; limited direct comparison across imaging modalities; and variable adjustment for confounders. CONCLUSIONS: Neuroimaging biomarkers, particularly ASPECTS, perfusion-derived metrics, collateral status, and markers of chronic small-vessel disease, provide important prognostic information for identifying patients at risk of futile recanalization despite successful thrombectomy. ABBREVIATIONS: AIS: Acute Ischemic Stroke; CCR: Cerebral Collateral Recycle; EVT: Endovascular Thrombectomy; FR: Futile Recanalization; HIR: Hypoperfusion Intensity Ratio; LVO: Large Vessel Occlusion; MT: Mechanical Thrombectomy; rCBV: Relative Cerebral Blood Volume; rLMC: Regional Leptomeningeal Collateral; VO: Venous Outflow.

1 July 2026 in Stroke
Verified
Journal Article
Closed access
HCHuanwen Chen
Huanwen Chen
MMMatthew McIntyre
Matthew McIntyre
JKJay Kakadiya
Jay Kakadiya
PRPranjal Rai
Pranjal Rai
MEMuhammed Amir Essibayi
Muhammed Amir Essibayi
DLDhairya A Lakhani
Dhairya A Lakhani
BACKGROUND: Unruptured intracranial aneurysms (UIAs) affect up to 5% of the population, and rupture can lead to devastating subarachnoid hemorrhage. GLP-1RAs (glucagon-like peptide-1 receptor agonists) have anti-inflammatory and vasculoprotective effects, but their impact on aneurysm stability and subarachnoid hemorrhage outcomes is unexplored. This study evaluated whether GLP-1RA use is associated with reduced rupture risk and attenuated severity in the event of a rupture. METHODS: We conducted a retrospective cohort study using the TriNetX US Collaborative Network (2016–2024). Cohort 1 included patients with newly diagnosed, untreated UIA; cohort 2 included those who suffered aneurysm rupture. GLP-1RA exposure was defined as use before or within 3 months of UIA diagnosis (cohort 1) or before rupture (cohort 2). The primary outcome was aneurysm rupture risk in cohort 1. Secondary outcomes include presentation severity, vasospasm, and mortality in cohort 2. Propensity score matching balanced demographics, comorbidities, and medications. RESULTS: After propensity score match, cohort 1 of patients with untreated UIA included 8088 GLP-1RA users and 8088 nonusers. GLP-1RA use was associated with significantly lower probabilities of aneurysm rupture at 1-year (0.65% versus 1.51%; P <0.001), 3-year (1.18% versus 1.85%; P <0.001), and 5-year (1.49% versus 2.10%; P <0.001) timepoints, representing a 48% decrease in hazards (hazard ratio, 0.52 [95% CI, 0.38–0.69]). Among patients who suffered aneurysm rupture (cohort 2, N=298 after propensity score match), prerupture GLP-1RA use (n=149) was associated with lower rates of intraparenchymal hemorrhage (17.4% versus 33.6%; P <0.001), intraventricular hemorrhage (10.1% versus 23.5%; P <0.001), and clinically significant vasospasm (10.7% versus 24.2%; P =0.002), as well as numerically lower rates of 30-day mortality (9.4% versus 14.1%; P =0.21). CONCLUSIONS: For patients with untreated UIA, GLP-1RA use was associated with a 48% reduction in aneurysm rupture risk and, among those who suffered aneurysm rupture, milder clinical and radiographic severity. These findings suggest possible neuroprotective and vascular stabilizing effects of GLP-1RAs for patients with UIA.

13 November 2025 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
JKJay Kakadiya
Jay Kakadiya
DLDhairya A Lakhani
Dhairya A Lakhani
Hamza A SalimHamza A Salim
Hamza A Salim
MKManisha Koneru
Manisha Koneru
DWDylan Wolman
Dylan Wolman
VYVivek S. Yedavalli
Vivek S. Yedavalli
Stroke remains a leading cause of death and disability worldwide, with anterior circulation large-vessel occlusion (AIS-LVO) representing a major contributor. While arterial parameters such as cerebral blood flow (CBF), cerebral blood volume (CBV), and time-to-maximum (Tmax) have traditionally been used to assess perfusion, they often fail to capture microvascular dysfunction following mechanical thrombectomy (MT). Emerging evidence highlights venous outflow (VO) parameters, particularly prolonged venous transit (PVT), as reliable predictors of functional outcomes. PVT, defined as delayed opacification (Tmax ≥ 10 s) of major dural venous sinuses on perfusion imaging, reflects impaired microcirculatory drainage and tissue hypoxia. Studies have demonstrated strong interobserver agreement and consistent associations between PVT+ status and worse NIHSS scores, larger infarct volumes, higher mortality, and poor 90-day modified Rankin Scale outcomes. Compared with arterial metrics, PVT offers superior prognostic performance and can complement established VO scores such as COVES, PRECISE, and CVO. Despite study heterogeneity, current evidence supports PVT as a simple, reproducible, and clinically meaningful biomarker. Standardization of PVT measurement and integration into multimodal prognostic models could refine post-recanalization risk stratification, guide adjunctive therapies, and improve patient outcomes in acute ischemic stroke. ABBREVIATIONS: AIS LVO – Acute Ischemic Stroke due to Large Vessel Occlusion; PVT – Prolonged Venous Transit; LOS – Length of Stay; COVES – Cortical Vein Opacification Score; PRECISE – Predicting Recanalization Effectiveness in Cortical Intravenous Sinus Embolism; CVO – Comprehensive Venous Outflow score; HIR – Hypoperfusion Intensity Ratio; SSS – Superior Sagittal Sinus

13 January 2026 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
JKJay Kakadiya
Jay Kakadiya
HCHuanwen Chen
Huanwen Chen
APArsh Patankar
Arsh Patankar
Hamza A SalimHamza A Salim
Hamza A Salim
MEMuhammed Amir Essibayi
Muhammed Amir Essibayi
DLDhairya A Lakhani
Dhairya A Lakhani
Background: Dual antiplatelet therapy (DAPT) is recommended around carotid artery stenting (CAS) to reduce periprocedural stroke risk. Clopidogrel is widely used, but response variability related to pharmacokinetics and CYP2C19 polymorphisms may limit its effectiveness. Ticagrelor is a more potent, direct acting P2Y12 inhibitor, but its comparative effectiveness in CAS remains uncertain. Methods: We conducted a retrospective cohort study in the TriNetX database, identifying adults with carotid artery stenosis who underwent CAS between January 2016 and August 2025 and received either ticagrelor or clopidogrel. Primary outcomes at 180 days included ischemic stroke, major hemorrhage, intracranial hemorrhage, and all cause mortality. Secondary outcomes included inpatient readmission and emergency department (ED) visits. Propensity score matching (1:1), Kaplan–Meier survival, and Cox proportional hazards analysis were used. Results: Among 6996 patients, 378 received ticagrelor and 6618 received clopidogrel; aspirin co-use was similar (89.7% vs 91.7%). After matching, 377 patients remained in each cohort. Ischemic stroke (2.7% vs 4.2%; HR 0.56, 95% CI 0.25 to 1.27; P=0.159) and major hemorrhage (2.9% vs 4.8%; HR 0.61, 95% CI 0.29 to 1.30; P=0.197) were numerically lower with ticagrelor. Rates of intracranial hemorrhage were similar (2.7% vs 2.7%; HR 0.61, 95% CI 0.14 to 2.53; P=0.488). Mortality was numerically higher with ticagrelor (3.4% vs 2.7%; HR 1.64, 95% CI 0.68 to 3.97; P=0.263). ED visits were similar (14.3% vs 14.6%; HR 0.97, 95% CI 0.67 to 1.42; P=0.895). Inpatient readmission was numerically lower with ticagrelor (15.9% vs 19.1%; HR 0.81, 95% CI 0.57 to 1.14; P=0.223). Conclusion: Ticagrelor and clopidogrel showed comparable safety and effectiveness following CAS. Future prospective genotype informed trials are warranted to confirm these findings.

21 May 2026 in Neurology International
Verified
Journal Article
Open access
PDF file
PRPranjal Rai
Pranjal Rai
DMDaniel Mandel
Daniel Mandel
GBGirish Bathla
Girish Bathla
VDVidhi Hiteshbhai Dhaduk
Vidhi Hiteshbhai Dhaduk
RRRadhika Rajeev
Radhika Rajeev
DLDhairya A Lakhani
Dhairya A Lakhani
Background: Asymptomatic intracranial atherosclerotic arterial stenosis (ICAS) is an underrecognized entity for which vascular risk-factor optimization is the primary management strategy, with no current indication for routine antiplatelet therapy or endovascular intervention for primary stroke prevention. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events, including stroke, in high-risk cardiometabolic populations, but their association with outcomes in asymptomatic ICAS is yet to be evaluated. The present study aims to evaluate the association between GLP-1RA use and cerebrovascular outcomes in adults with asymptomatic ICAS. Materials and Methods: We used the TriNetX US Collaborative Network (71 healthcare organizations) to identify adults (≥18 years) with ICAS between 1 January 2016 and 31 December 2025, and excluded patients with prior cerebral infarction, intracranial hemorrhage, or cerebrovascular ischemic syndromes. Exposure was defined as initiation of any GLP-1 receptor agonist (lixisenatide, semaglutide, liraglutide, tirzepatide, dulaglutide) during the 6 months before or on the date of index ICAS diagnosis. Outcomes were assessed at 1 year, and included ischemic stroke, all-cause mortality, and a composite of ischemic stroke or mortality. Propensity-score matching (1:1) was performed, including demographics, vascular risk factors, comorbidities, antithrombotics, lipid/diabetes therapies, and cardiometabolic laboratory/physiologic measures. Results: Before matching, 1746 GLP-1RA users and 71,792 non-users met inclusion criteria; after matching, 1728 patients remained in each cohort. GLP-1RA use was associated with lower 1-year risk of ischemic stroke (4.40% vs. 6.10%; hazard ratio [HR] 0.70, 95% CI 0.52–0.95; p = 0.044), lower all-cause mortality (3.40% vs. 9.40%; HR 0.35, 95% CI 0.26–0.47; p < 0.001), and lower composite outcome risk (7.50% vs. 15.00%; HR 0.48, 95% CI 0.39–0.59; p < 0.001). Notably, these associations were observed despite matching for HbA1c, LDL cholesterol, BMI, and systolic blood pressure, suggesting potential effects beyond measured cardiometabolic risk profiles. Conclusions: In this large, propensity-matched cohort of adults with a-ICAS, GLP-1RA use was associated with lower ischemic stroke, all-cause mortality, and composite outcome at 1 year. These findings are hypothesis-generating and require further prospective studies to confirm this observation.

11 April 2026 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
HCHuanwen Chen
Huanwen Chen
JKJay Kakadiya
Jay Kakadiya
HSHamza A. Salim
Hamza A. Salim
MEMuhammed Amir Essibayi
Muhammed Amir Essibayi
AAAmelia Adcock
Amelia Adcock
DLDhairya A Lakhani
Dhairya A Lakhani